July 15, 2025 02:58 PM EDTUpdated 05:34 PM

BMS warns against ‘indiscriminate use’ of renegotiations as CMS plans next drug price talks

Nicole DeFeudis

Editor

Bristol Myers Squibb is calling for transparency in drug price talks if the government selects products for renegotiation under the Inflation Reduction Act, cautioning against …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BMS warns against ‘indiscriminate use’ of renegotiations as CMS plans next drug price talks

Nicole DeFeudis

Editor

Sign up to read this article for free.

AstraZeneca says amyloidosis drug fails Phase 3 trials, but claims potential in undisclosed subgroup

Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfront

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43%

The Trump administration disbanded a newborn screening panel. Advocates now face a harder path

As PEPFAR funding gets a lifeline, HIV leaders warn of regression for the field

BMS warns against ‘in­dis­crim­i­nate use’ of rene­go­ti­a­tions as CMS plans next drug price talks

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

As­traZeneca says amy­loi­do­sis drug fails Phase 3 tri­als, but claims po­ten­tial in undis­closed sub­group

De­bio­pharm li­cens­es Re­pare’s first-in-class can­cer drug for $10M up­front

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

J&J's Ste­lara faces con­tin­ued biosim­i­lar com­pe­ti­tion, with Q2 rev­enue falling 43%

The Trump ad­min­is­tra­tion dis­band­ed a new­born screen­ing pan­el. Ad­vo­cates now face a hard­er path

As PEP­FAR fund­ing gets a life­line, HIV lead­ers warn of re­gres­sion for the field

BMS warns against ‘indiscriminate use’ of renegotiations as CMS plans next drug price talks

AstraZeneca says amyloidosis drug fails Phase 3 trials, but claims potential in undisclosed subgroup

Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfront

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43%

The Trump administration disbanded a newborn screening panel. Advocates now face a harder path

As PEPFAR funding gets a lifeline, HIV leaders warn of regression for the field